Edited by
Brian Metcalf, Chief Drug Discovery Officer, Incyte Corporation, Moraga, CA, U.S.A.
Susan Dillon, Senior Vice President, Discovery Research Centocor, Johnson & Johnson, Malvern, PA, U.S.A.
Description
This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed
description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section
looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and
Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics,
present new possible small molecule therapeutics and serve as the focus of the final section of the book.
Audience:
Professionals in biotechnology and pharmaceutical drug discovery and clinical development. Can also include students and academics in the related areas of study.
